Attending physician
National Taiwan University Hospital, Taiwan (Republic of China)
Dr. Tom W. Chen is currently an attending physician at the Department of Oncology, National Taiwan University Hospital (NTUH) in Taipei, Taiwan. Dr. Chen received internal medicine training followed by a fellowship course as a medical oncologist in NTUH. Afterwards, he joined Drug Development Program (DDP) in Princess Margaret Cancer Centre in Toronto, Canada as a clinical fellow to study early phase clinical trials with Dr. Lillian Siu and Dr. Phil Bedard. During his stay in Princess Margaret, he gained more experience with next-generation sequencing and precision medicine, as well as interest in sarcoma patients.
After returning to NTUH, he faciliated in the establishement of sarcoma multi-disciplinary team. He is actively involved in many sarcomca clinical trials including the global phase III study of doxorubucin +/- olaratumab in advanced soft tissue sarcoma and is also the institution PI of the single arm phase II study of tazemetostat (an EZH2 inhibtor) for synovical sarcoma, epithelioid sarcoma, and INI-1 negative cancers. He has also initiatied investgiator-led cinical trials in soft tissue sarcoma investigating the combination of lenvatinib and eribulin in leiomyosarcoma and liposarcoma (LEADER), which was selected as an oral presentation in the ASCO 2020 Virtual Meeting. He also collaborated with the Dr. Wolf Fridman and Catherine Sautes-Fridman of the Cordelier Research Center in Paris about the immune microenviroment of soft tissue sarcoma. The collaborative research that demonstrated the important role of B cells and tertiary lymphoid structure in soft tissue sarcom was also recently published in Nature.
